Tag: cancer

WIN Consortium Leading the Future of Precision Cancer Medicine

March 18, 2025

"Our vision is to accelerate the future of precision oncology care.” BUFFALO, NY - March 18, 2025 – A new precision oncology paper was published in Oncotarget, Volume 16, on… read more

Oncotarget

Oncotarget to Participate at the AACR Annual Meeting 2025

March 17, 2025

Oncotarget is honored to participate in the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in Chicago. BUFFALO, NY - March 17, 2025 – Impact… read more

Oncotarget

Pitfalls of FDA-Approved Germline Cancer Predisposition Tests

December 30, 2024

“The FDA approval on September 29, 2023, for 'class III de novo' blood tests to assess hereditary cancer risk make widely available tests that may be obtained through a Direct… read more

Oncotarget

Generative AI in Cancer Imaging: Revolutionizing Detection & Diagnosis

September 6, 2024

“This editorial explores its impact on expanding datasets, improving image quality, and enabling predictive oncology.” BUFFALO, NY- September 6, 2024 – A new editorial was published in Oncotarget's Volume 15… read more

Oncotarget

Genotype Matters: Tailored Screening for Germline CHEK2 Variants

August 26, 2024

“In our study, we postulated that these differences were driven by three common low-risk (LR) missense variants: p.I157T, p.S428F, and p.T476M, all of which have a BC odds ratio of… read more

Oncotarget

Disrupting NKG2A:HLA-E Interactions for Enhanced Anti-Cancer Immunity

August 21, 2024

“[...] there is strong preclinical evidence that disruption of NKG2A interactions with HLA-E can stimulate both NK cell and cytotoxic T cell effector functions against cancer.” BUFFALO, NY- August 21,… read more

Oncotarget

Nanobody Inhibits Metastasis of Breast Tumor Cells to Lung in Mice

August 15, 2024

“In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” BUFFALO, NY- August 15, 2024 –… read more

Targeting the multifaceted BRAF in cancer: New directions

Oncotarget

New Directions in Targeting the Multifaceted BRAF in Cancer

August 12, 2024

“Here we discuss the diverse forms of BRAF alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.” BUFFALO, NY- August 12,… read more

Oncotarget

Dealing with Runaway Metastatic Disease

August 7, 2024

"Metastatic disease remains a major issue in daily practice in oncology because the outcome is still often fatal.” BUFFALO, NY - August 7, 2024 – A new editorial paper was… read more

INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death

Oncotarget

INT-1B3 miR-193a-3p Mimic Boosts T Cell Immunity and Induces Tumor Cell Death

August 5, 2024

“INT-1B3 inhibited distant tumor metastasis and significantly prolonged survival.” BUFFALO, NY- August 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 12, 2024, entitled,… read more